Cargando…

Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects

BACKGROUND: A once-daily (o.d.) fixed-dose combination of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF) delivered via the Breezhaler(®) device (IND/GLY/MF) is being developed for treatment of asthma. This study compared steady-state pharmacokinetics of IND, GLY...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Satoru, Vaidya, Soniya, Tillmann, Hanns-Christian, Sakita, Yohei, Machineni, Surendra, Heudi, Olivier, Furihata, Kenichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791651/ https://www.ncbi.nlm.nih.gov/pubmed/33413291 http://dx.doi.org/10.1186/s12890-020-01382-6

Ejemplares similares

Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler(®) Device in Patients with Asthma
por: Bartels, Christian, et al.
Publicado: (2021)

Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma
por: Chapman, Kenneth R., et al.
Publicado: (2021)

Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial
por: Beier, Jutta, et al.
Publicado: (2021)

Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study
por: Watz, Henrik, et al.
Publicado: (2020)

A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
por: Brittain, Dominic, et al.
Publicado: (2022)

Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
por: Mtibaa, Mondher, et al.
Publicado: (2021)

Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial
por: Singh, Dave, et al.
Publicado: (2022)

Medication Adherence and Asthma Control with Once-Daily Indacaterol/Glycopyrronium/Mometasone Furoate Breezhaler Digital Companion: 90-Day Analysis from Germany
por: Woehrle, Holger, et al.
Publicado: (2023)

Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients
por: Miller, David, et al.
Publicado: (2020)

Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease
por: Kosoglou, Teddy, et al.
Publicado: (2013)

Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses
por: van Zyl-Smit, Richard N., et al.
Publicado: (2023)

Long-term safety of Mometasone Furoate administered via a dry powder inhaler in children: Results of an open-label study comparing Mometasone Furoate with Beclomethasone Dipropionate in children with persistent asthma
por: Noonan, Michael, et al.
Publicado: (2009)

Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma
por: van Zyl-Smit, Richard N, et al.
Publicado: (2023)

Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population
por: Sagara, Hironori, et al.
Publicado: (2021)

Efficacy of mometasone furoate and fluticasone furoate on persistent allergic rhinoconjunctivitis
por: Aneeza, W. Hamizan, et al.
Publicado: (2013)

Use of tiotropium bromide in an adolescent with adrenal suppression secondary to inhaled mometasone furoate
por: Hanna, Mariam, et al.
Publicado: (2014)

Mometasone furoate in the management of asthma: a review
por: Tan, Ricardo A, et al.
Publicado: (2008)

Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
por: Prakash, Anoop, et al.
Publicado: (2015)

Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial
por: Beasley, Richard W, et al.
Publicado: (2015)

Effectiveness of 0.1% mometasone furoate under hydrocolloid dressing versus 0.1% mometasone furoate in patients with lichen simplex chronicus
por: Lo, Hiu Lai, et al.
Publicado: (2023)

Inhaled mometasone furoate for the management of refractory oral corticosteroid-dependent asthma: a case report
por: Nsouli, Talal M
Publicado: (2009)

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study
por: Salomon, Joerg, et al.
Publicado: (2017)

Real-life effectiveness of indacaterol/glycopyrronium/mometasone for symptomatic relief of cough after switching from inhaled corticosteroid/long-acting β(2)-agonist therapy in patients with asthma: REACH study design
por: Niimi, Akio, et al.
Publicado: (2023)

Mometasone furoate nasal spray: a systematic review
por: Passali, Desiderio, et al.
Publicado: (2016)

Mometasone furoate is not superior to saline for chronic rhinitis in the elderly
por: Carvalho, Victor, et al.
Publicado: (2019)

Nasal Absorption Enhancement of Mometasone Furoate Nanocrystal Dispersions
por: Masuda, Shuya, et al.
Publicado: (2023)

Zein nanoparticles as oral carrier for mometasone furoate delivery
por: Zimath, Priscila, et al.
Publicado: (2023)

Development of simple and fast UV-method for the quantitative determination of mometasone furoate in a large number of metered doses of an aqueous nasal spray of mometasone furoate
por: Levin, Mykhaylo, et al.
Publicado: (2019)

Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation
por: Lage, Nayara Almeida, et al.
Publicado: (2023)

Suppression of Cytokine Release by Fluticasone Furoate vs. Mometasone Furoate in Human Nasal Tissue Ex-Vivo
por: Zhang, Nan, et al.
Publicado: (2014)

A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis
por: Yanez, Anahi, et al.
Publicado: (2016)

Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis
por: Doulaptsi, Maria, et al.
Publicado: (2021)

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis
por: Muro, Shigeo, et al.
Publicado: (2019)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
por: Gong, Shiyi, et al.
Publicado: (2021)

Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year
por: Mangia, Pier Paolo, et al.
Publicado: (2021)

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study
por: Price, David, et al.
Publicado: (2010)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Significant receptor affinities of metabolites and a degradation product of mometasone furoate
por: Valotis, Anagnostis, et al.
Publicado: (2004)

One-year treatment with mometasone furoate in chronic obstructive pulmonary disease
por: Calverley, Peter MA, et al.
Publicado: (2008)

Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery
por: Madan, Jyotsana R, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_skhd5i31d4ekuur64p0nh87k5m